• Capital raise of $27.5 million to support the ACCENT and AMPLICITY trials and kRAS and ovarian cancer trials
• Institutional placement to raise A$25 million and a Share Purchase Plan seeking to raise an additional A$2.5 million
• New shares issued under the Placement at $0.23 each

Amplia Therapeutics Limited (ASX: ATX) has undertaken a successful A$25.0 million institutional placement (Placement) of new, fully paid ordinary shares at a price of $0.23 per share. The Placement will be followed by a share purchase plan (SPP) seeking to raise $2.5 million (with the ability to accept over-subscriptions of up to an additional $7.5 million) at the SPP offer price. Amplia has received firm commitments for $2.5 million worth of shortfall shares under the SPP in the event of a shortfall. The funds from the capital raise will support Amplia's ongoing clinical studies, including the ACCENT and AMPLICITY trials, as well as planning for follow-on trials for its lead drug, narmafotinib (AMP945), in kRAS and ovarian cancer. Top-line data from the ACCENT trial is expected in late July/early August 2025, and the capital raise will enable the company to accelerate towards commencement of a potential pivotal phase 2b/3 trial in the second half of 2026. Following the capital raise, the company will be funded into 2027.

The company expects to receive R&D tax refunds of $8.2 million in FY25 and FY26, in addition to the $27.5 million capital raise, to fund the ACCENT and AMPLICITY trials, kRAS and ovarian cancer trials, CMC (manufacturing), and operations, preclinical, working capital and offer costs.